Table 1.
Characteristics of the Study Population and Pregnancy Outcomes
| Median (Range)a or Number of Subjects (%)b | |
|---|---|
|
| |
| Maternal Demographics | |
|
| |
| Age (years) at 3rd trimestera | 30.8 (13.5 – 39.2) |
|
| |
| Weight (kilograms) at 3rd trimestera | 80.6 (50.8 – 121.9) |
|
| |
| Race/Ethnicityb | |
| Hispanic, Latina | 15 (41) |
| Black, non-Hispanic | 10 (27) |
| White, non-Hispanic | 9 (24) |
| Asian, Pacific Islander | 1 (3) |
| More than one race | 1 (3) |
| Unknown/missing | 1 (3) |
|
| |
| CD4+ count (cells/mm3) at deliverya | 469 (9 – 1494) |
|
| |
| Women with plasma HIV RNA at:b | |
| 2nd Trimester | |
| Undetectable (< 400 copies/mL)* | 4/4 (100) |
| Detectable (≥ 400 copies/mL) | 0/4 (0) |
| 3rd Trimester | |
| Undetectable (< 400 copies/mL)† | 33/35 (94) |
| Detectable (≥ 400 copies/mL) | 2/35 (6) |
| Delivery | |
| Undetectable (< 400 copies/mL)‡ | 33/34 (97) |
| Detectable (≥ 400 copies/mL) | 1/34 (3) |
| Postpartum | |
| Undetectable (< 400 copies/mL)§ | 22/26 (85) |
| Detectable (≥ 400 copies/mL) | 11/26 (15) |
|
| |
| Concomitant antiretrovirals | |
| Emtricitabine | 25 |
| Atazanavir (with rtv) | 16 |
| Lopinavir/ritonavir | 12 |
| Lamivudine | 10 |
| Zidovudine | 7 |
| Nelfinavir | 4 |
| Abacavir | 3 |
| Saquinavir (with rtv) | 2 |
| Didanosine, efavirenz, fosamprenavir (with rtv), nevirapine | 1 each |
|
| |
| Pregnancy Outcomes | |
|
| |
| Gestational age at delivery (weeks)a | 38.1 (34.7 – 41.7) |
|
| |
| Infant birth weight (kilograms) | 2.93 (2.23 – 4.05) |
a
Median (range)
b
Number of subjects (percent)
*
3/4 (75%) subjects were < 50 copies per milliliter.
†
22/35 (63%) subjects were < 50 copies per milliliter.
‡
20/34 (59%) subjects were < 50 copies per milliliter.
§
11/26 (42%) subjects were < 50 copies per milliliter.